Caprock Group LLC Invests $2.59 Million in Teva Pharmaceutical Industries Ltd. $TEVA

Caprock Group LLC bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 141,096 shares of the company’s stock, valued at approximately $2,593,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Cromwell Holdings LLC increased its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after acquiring an additional 629 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $41,000. LRI Investments LLC increased its holdings in Teva Pharmaceutical Industries by 246.0% in the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. JTC Employer Solutions Trustee Ltd acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $65,000. Finally, MAI Capital Management raised its position in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $33.92 on Friday. The firm has a fifty day moving average of $31.97 and a two-hundred day moving average of $24.31. The firm has a market cap of $38.90 billion, a P/E ratio of 28.27, a P/E/G ratio of 1.95 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the transaction, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TEVA has been the subject of several analyst reports. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Finally, Barclays raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $37.11.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.